Navigation Links
Need for Blood Transfusions reduced

The need for blood transfusions among critically ill patients may now be reduced by a new substance. A study showed that patients in intensive care with a lowered need for transfusion were the ones who had received weekly administration //of the man-made protein.

Researchers examined the effectiveness of a substance called recombinant human erythropoietin, or rHuEPO, that stimulates the body to produce new red blood cells and is meant to decrease the number of red blood cell transfusions. Erythropoietin, produced in the kidney, stimulates the production of red blood cells.

Study was conducted at 67 centers with 1,305 patients who had been in the ICU for two days and were expected to stay there for at least two more days. Participants were assigned to receive either a placebo or 40,000 units of rHuEPO on day three in the ICU and weekly while in the hospital.

Results show that patients who received rHuEPO were less likely to receive a transfusion. More than 59 percent of patients taking the placebo had transfusions in contrast to 50.6 percent of patients taking rHuEPO. Around 18 percent reduction in total blood units transfused and a greater increase in haemoglobin was found in the rHuEPO administered group. Study also indicated that rHuEPO did not improve survival or clinical outcomes.


'"/>




Page: 1

Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Blood clots likely in long travel
4. Hemochromatosis Patients Blood is Safe
5. Blood transfusions beneficial after heart attacks
6. Blood Pressure Drug may slow wasting in burn victims
7. Levels Of Blood Proteins May Help Heart Disease Care
8. Blood test may identify ovarian cancer
9. A Blood test for suicide risk?
10. Blood Pressure Drugs maintain muscle strength
11. Blood test diagnoses heart failure in short time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the United ... persecution, Center for Medicine after the Holocaust (CMATH) announced that it will ... and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany and ...
(Date:4/24/2017)... ... , ... Today, Bright Pink , a national non-profit organization focusing on the prevention and ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive Officer. ... as Chairman of the Board and launched a national search to find a visionary ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the ... life forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her ... I began journaling conversations and situations throughout my divorce,” James said. “After the death ...
(Date:4/24/2017)... ... 2017 , ... The world-class designers of Happy Gadget Alert ... lifesaving device for the everyday use of parents worldwide. It is a lightweight, ... a child’s vital signs, and detect unusual symptoms or physical patterns. This innovative ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: